Who mentions $INBS most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $INBS most — 5 mentions in the past 12 months.

When was $INBS first mentioned on Surfaced?

The earliest tracked mention of $INBS in the Surfaced archive was on Jul 14, 2026.

How many voices track $INBS?

1 FinTwit voice has mentioned $INBS 5 times in the past 12 months.

What kind of voices mention $INBS most?

$INBS is mentioned most by Long Research voices on Surfaced.

$INBS — FinTwit mentions on Surfaced

Recent mentions

5 mentions

@investmentguru_Jul 14, 2026 · 7:29 PM

$INBS : The FDA Pathway Gets Closer Intelligent Bio Solutions continues to advance its FDA 510(k) submission process for its Intelligent Fingerprinting Drug Screening System. The latest milestone: an Interference Study designed to prove the system can maintain accuracy and specificity even in real-world conditions where common substances may impact testing. Why this matters: • Regulatory validation is a critical step toward U.S. market entry • Data from the study will support the FDA submission package • Successful clearance could significantly expand the company’s addressable market The technology is moving from innovation toward commercialization. Still an early-stage biotech/med-tech story, but the upcoming FDA milestone is the key catalyst to watch. $INBS Paid partnership @TheTitanMedia Not financial advice. Disclaimer: https://t.co/zZ4gRC1ut7

Open on X

@investmentguru_Jul 14, 2026 · 5:36 PM

$INBS turning green

Open on X

@investmentguru_Jul 14, 2026 · 2:30 PM

$INBS: Beyond Drug Testing — A Biosensor Platform Story 🧬 The bigger opportunity with Intelligent Bio Solutions may not stop at workplace drug testing. The company’s fingerprint-based technology is built around analyzing biomarkers from non-invasive samples like sweat. Future applications could include: • Health monitoring • Biomarker detection • Immunology applications • Allergy-related testing The current focus is FDA clearance for codeine detection — but investors are watching the broader platform potential. Small-cap medical technology companies often start with one application before expanding into larger markets. $INBS High risk, high reward. Always do your own research. Disclaimer: https://t.co/zZ4gRC1ut7 Paid partnership.

Open on X

@investmentguru_Jul 14, 2026 · 2:00 PM

$INBS: Another Step Toward FDA Clearance. Intelligent Bio Solutions announced the start of its Interference Study, an important part of the FDA 510(k) submission process for its Intelligent Fingerprinting Drug Screening System. The study is designed to validate that the system maintains accuracy and specificity for codeine detection even in real-world conditions where potential interfering substances may be present. Key points: • Study conducted with CenExel Clinical Research • 75 healthy adult participants enrolled • Results expected by mid-July 2026 • Data will be included alongside the Method Comparison Study in the FDA submission package FDA clearance remains the major catalyst for INBS, potentially opening access to the much larger U.S. market. The company is moving from technology development toward regulatory validation — an important phase for any emerging medical technology platform. High risk, high reward micro-cap. Regulatory approval and execution remain the key factors to watch. Not financial advice. Paid partnerships, see disclaimer in original post

Open on X

@investmentguru_Jul 14, 2026 · 1:30 PM

$INBS: A Small-Cap Healthcare Company With a Big Market Opportunity. Most investors have never heard of Intelligent Bio Solutions — and that’s often where early opportunities begin. $INBS is developing a non-invasive fingerprint-based drug testing platform that uses fingertip sweat to detect substances like opiates, cocaine, methamphetamine, cannabis, and benzodiazepines. No blood draws, no complicated collection process, and results in minutes. The bigger story is that this is not just a drug-testing company. The underlying biosensor technology has potential applications across healthcare, including biomarker and allergen detection. Commercial traction is already developing: • 450+ customers across 24 countries • Used across industries including construction, mining, transportation, logistics, and law enforcement • Growing recurring cartridge revenue model The major catalyst: FDA clearance. A successful 510(k) pathway could unlock the much larger U.S. market and significantly expand the company’s opportunity. Like many micro-cap healthcare companies, risk remains high — execution, regulatory approval, and funding will be key factors. But the combination of real customers, proprietary technology, and a large addressable market makes INBS an interesting company to watch. Small company. Big ambition. Potentially significant market opportunity. Disclaimer: https://t.co/zZ4gRC1ut7 #advertisement Paid advertisement. Not financial advice. Always do your own research.

Open on X

Frequently asked